APOPHARMA USA Trademark

Trademark Overview


On Wednesday, March 30, 2016, a trademark application was filed for APOPHARMA USA with the United States Patent and Trademark Office. The USPTO has given the APOPHARMA USA trademark a serial number of 86958426. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, July 13, 2020. This trademark is owned by Apotex Technologies Inc.. The APOPHARMA USA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, prescription drugs for the treatment of multiple myeloma by slowing the growth of cancer cells, prescription drugs for the treatment of multiple myeloma by stopping the growth of cancer cells, prescription drugs for palliative treatment of patients with multiple myeloma, and prescription drugs for use as an iron chelator for the treatment of patients with transfusion iron overload due to thalassemia syndromes, prescription drugs for the treatment of iron-associated neurodegenerative conditions, namely, Parkinson's disease and neurodegeneration with brain iron accumulation, in particular, pantothenate kinase-associated neurodegeneration
apopharma usa

General Information


Serial Number86958426
Word MarkAPOPHARMA USA
Filing DateWednesday, March 30, 2016
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, July 13, 2020
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, April 11, 2017

Trademark Statements


Indication of Colors claimedColor is not claimed as a feature of the mark.
Disclaimer with Predetermined Text"USA"
Description of MarkThe mark consists of the word "APOPHARMA" with "USA" underneath and a swoosh design at the end.
Goods and ServicesPharmaceutical preparations, namely, prescription drugs for the treatment of multiple myeloma by slowing the growth of cancer cells, prescription drugs for the treatment of multiple myeloma by stopping the growth of cancer cells, prescription drugs for palliative treatment of patients with multiple myeloma, and prescription drugs for use as an iron chelator for the treatment of patients with transfusion iron overload due to thalassemia syndromes, prescription drugs for the treatment of iron-associated neurodegenerative conditions, namely, Parkinson's disease and neurodegeneration with brain iron accumulation, in particular, pantothenate kinase-associated neurodegeneration
Pseudo MarkAPO PHARMA USA

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, April 4, 2016
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAPOTEX INC.
Party Type21 - New Owner After Publication
Legal Entity Type03 - Corporation
AddressTORONTO, ONTARIO M9L1T9
CA

Party NameApotex Technologies Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressToronto, Ontario M9L1T9
CA

Party NameApotex Technologies Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressToronto, Ontario M9L1T9
CA

Trademark Events


Event DateEvent Description
Monday, July 13, 2020ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, July 13, 2020ABANDONMENT - NO USE STATEMENT FILED
Tuesday, November 5, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, November 4, 2019EXTENSION 5 GRANTED
Thursday, October 31, 2019EXTENSION 5 FILED
Monday, November 4, 2019CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, October 31, 2019TEAS EXTENSION RECEIVED
Wednesday, June 19, 2019AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Thursday, May 9, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, May 7, 2019EXTENSION 4 GRANTED
Tuesday, May 7, 2019EXTENSION 4 FILED
Tuesday, May 7, 2019TEAS EXTENSION RECEIVED
Friday, December 7, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, December 5, 2018EXTENSION 3 GRANTED
Wednesday, December 5, 2018EXTENSION 3 FILED
Wednesday, December 5, 2018TEAS EXTENSION RECEIVED
Thursday, June 7, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, June 5, 2018EXTENSION 2 GRANTED
Tuesday, June 5, 2018EXTENSION 2 FILED
Tuesday, June 5, 2018TEAS EXTENSION RECEIVED
Thursday, December 7, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, December 5, 2017EXTENSION 1 GRANTED
Tuesday, December 5, 2017EXTENSION 1 FILED
Tuesday, December 5, 2017TEAS EXTENSION RECEIVED
Tuesday, June 6, 2017NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, April 11, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 11, 2017PUBLISHED FOR OPPOSITION
Wednesday, March 22, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, March 3, 2017LAW OFFICE PUBLICATION REVIEW COMPLETED
Thursday, February 23, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, February 8, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, February 8, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, January 31, 2017ASSIGNED TO LIE
Wednesday, January 11, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, July 19, 2016NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, July 19, 2016NON-FINAL ACTION E-MAILED
Tuesday, July 19, 2016NON-FINAL ACTION WRITTEN
Wednesday, July 13, 2016ASSIGNED TO EXAMINER
Tuesday, April 5, 2016NOTICE OF DESIGN SEARCH CODE E-MAILED
Monday, April 4, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Saturday, April 2, 2016NEW APPLICATION ENTERED IN TRAM